Share

June 2016; 3 (3) ArticleOpen Access

Evidence of a pathogenic role for CD8+ T cells in anti-GABAB receptor limbic encephalitis

Kristin S. Golombeck, Kathrin Bönte, Constanze Mönig, Karen M. van Loo, Marvin Hartwig, Wolfram Schwindt, Guido Widman, Matthias Lindenau, Albert J. Becker, Markus Glatzel, Christian E. Elger, Heinz Wiendl, Sven G. Meuth, Hubertus Lohmann, Catharina C. Gross, Nico Melzer
First published April 29, 2016, DOI: https://doi.org/10.1212/NXI.0000000000000232
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
1198

Share

Abstract

Objectives: To characterize the cellular autoimmune response in patients with γ-aminobutyric acid (GABA)B receptor antibody–associated limbic encephalitis (GABAB-R LE).

Methods: Patients underwent MRI, extensive neuropsychological assessment, and multiparameter flow cytometry of peripheral blood and CSF.

Results: We identified a series of 3 cases of nonparaneoplastic GABAB-R LE and one case of paraneoplastic GABAB-R LE associated with small cell lung cancer. All patients exhibited temporal lobe epilepsy, neuropsychological deficits, and MRI findings typical of LE. Absolute numbers of CD19+ B cells, CD138+ CD19+ plasma cells, CD4+ T cells, activated HLADR+ CD4+ T cells, as well as CD8+ T cells and HLADR+ CD8+ T cells did not differ in peripheral blood but were elevated in CSF of patients with GABAB-R LE compared to controls. Augmented absolute numbers of CD138+ CD19+ plasma cells and activated HLADR+ CD8+ T cells in CSF corresponded to higher overall neuropsychological and memory deficits in patients with GABAB-R LE. A histologic specimen of one patient following selective amygdalohippocampectomy revealed perivascular infiltrates of CD138+ plasma cells and CD4+ T cells, whereas cytotoxic CD8+ T cells were detected within the brain parenchyma in close contact to neurons.

Conclusion: Our data suggest a pathogenic role for CD8+ T cells in addition to the established role of plasma cell–derived autoantibodies in GABAB-R LE.

GLOSSARY

AVLT=
Auditory Verbal Learning Test;
FLAIR=
fluid-attenuated inversion recovery;
GABA=
γ-aminobutyric acid;
GABAB-R=
γ-aminobutyric acid B receptor;
GAD65=
glutamic acid decarboxylase, 65-kDa isoform;
Ig=
immunoglobulin;
LE=
limbic encephalitis;
PB=
peripheral blood;
SCLC=
small cell lung cancer

Limbic encephalitis with autoantibodies against synaptic and extrasynaptic neuronal γ-aminobutyric acid (GABA)B receptors (GABAB-R LE) is associated with small cell lung cancer (SCLC) in about 50% of all patients.1,–,4 Clinically, patients present with mesial temporal lobe epilepsy, memory disturbance, and a variety of neuropsychiatric symptoms.1,–,4 MRI in about two-thirds of all cases reveals volume increase and hyperintense signals in one or both mesial temporal lobes on T2-weighted and fluid-attenuated inversion recovery (FLAIR)-weighted sequences suggesting temporomesial encephalitis.1,–,4 EEG usually shows slowing and epileptic activity in one or both anterior temporal lobes.1,–,4 Autoantibodies can be detected in serum, CSF, or both and recognize an extracellular domain of the B1-subunit of the GABAB receptor mainly expressed in hippocampus, amygdala, thalamus, and cerebellum.4 GABAB receptors mediate pre- and postsynaptic GABAergic inhibition and thereby suppress high-activity states with excessive synchronization and thus seizure generation in neuronal networks. Genetic disruption or pharmacologic blockade of the GABAB receptor in animal models causes excessive neuronal excitability, as well as disturbance of learning, memory, and behavior4 resembling the clinical phenotype of human GABAB-R LE. Moreover, patients with GABAB-R LE have been reported to respond at least partially to antibody-depleting immunotherapies and tumor therapy.1,–,4 Hence, autoantibodies are considered pathogenic. In a subset of patients, GABAB-R antibodies have been reported to occur together with antibodies to the 65-kDa isoform of glutamic acid decarboxylase (GAD65) and classic onconeuronal proteins (Hu, Ri, amphiphysin, SOX1), suggesting the presence of an autoimmune response to both intracellular and plasma membrane neuronal antigens in these patients.1,–,6 However, except for the presence of autoantibodies in serum and CSF, little is known on the (auto)immune response in this novel CNS disorder.

Herein, we provide a detailed description of the composition of peripheral blood (PB) and CSF-infiltrating immune cells and confirm their presence in the inflamed limbic system and their relation to neuropsychological deficits in 4 cases of GABAB-R LE.

METHODS

Patients and controls.

Patients with GABAB-R LE and controls were recruited at the Department of Neurology, University of Münster, Germany, or the Department of Epileptology, University of Bonn, Germany, and analyzed using flow cytometry at the Department of Neurology, University of Münster, Germany. Patients and controls underwent physical, neurologic, and psychiatric examination by a trained physician. PB and CSF were taken from patients and controls and analyzed by routine and multiparameter flow cytometry. In addition, routine EEG using the 10-20 system and/or video-EEG monitoring, MRI of the brain at 1.5 or 3.0 tesla, and a comprehensive neuropsychological test battery were conducted.

Standard protocol approvals, registrations, and patient consents.

The study was approved by the local ethics committee of the medical faculty of the University of Münster, Germany (Az 2013-350-f-S). All participants or their nearest relatives gave written informed consent to the study including scientific evaluation and publication of all clinical and paraclinical data obtained.

Multiparameter flow cytometry of PB and CSF.

PB and CSF of all patients were immediately obtained after admission. PB and CSF of healthy controls were obtained from 26 individuals with suspected presence of a neurologic disorder who retrospectively were determined to have somatization disorders.7 In addition to the clinical classification, patients included in the control group also fulfilled the following laboratory criteria defining a noninflammatory CSF: <5 cells/μL, <500 mg protein/mL, <2 mM lactate, no disruption of the PB–CSF barrier (defined by the CSF/serum albumin ratio), no intrathecal immunoglobulin (Ig)G, IgA, or IgM synthesis (Reiber criteria),7,8 and no CSF-specific oligoclonal bands on isoelectric focusing.

Potential disease-related changes in the cellular composition of both PB and CSF compartments were analyzed using multiparameter flow cytometry.9 CSF samples were obtained by lumbar puncture, collected in polypropylene tubes, and were processed within 30 minutes. Cells were obtained from EDTA blood by erythrocyte lysis using VersaLyse buffer (Beckman Coulter, Germany) following the manufacturer's instructions. Cells were obtained from CSF by centrifugation (15 minutes, 290g, 4°C) and incubation in VersaLyse buffer. Cells were stained using the following fluorochrome-conjugated antibodies: CD14-FITC, CD138-PE, HLA-DR-ECD, CD3-PC5.5, CD56-PC7, CD4-APC, CD19-APCAlexafluor700, CD16-APCAlexafluor750, CD8-PacificBlue, and CD45-KromeOrange (all Beckman Coulter) and analyzed by 2 blinded authors (M.H., C.C.G.) using the Navios (Beckman Coulter). The gating strategy to determine leukocyte subsets in PB and CSF cells was performed as described.7 Absolute cell numbers were analyzed using Flow-Count Fluorospheres (Beckmann Coulter) according to the manufacturer's instructions.

Antineuronal antibody testing.

Serum and CSF were tested for the presence of IgG antibodies against intracellular neuronal antigens (ANNA1 [Hu], ANNA2 [Ri], ANNA3, PCA1 [Yo], PCA2, Tr/DNER, Ma1/2, CV2/CRMP5, amphiphysin, SOX1, GAD65) and neuronal surface membrane antigens (NMDA receptor, AMPA receptor, GABAA receptor, GABAB receptor, glycine receptor, CASPR2, LGI1, and VGKC) using established assays (EUROIMMUN, Lübeck, Germany10,11).

Neuropsychological assessment.

All patients were assessed by a comprehensive neuropsychological test battery conducted by experienced neuropsychologists (H.L., K.B.). The test battery assesses the full range of neuropsychological domains as presented in table e-1 at Neurology.org/nn. The test scores represent the individual percentile rank in comparison to neurologically healthy adults matched for age and level of education.

Magnetic resonance imaging.

Standard MRI was performed on 1.5- or 3.0-tesla scanners. Diffusion-weighted imaging with calculation of apparent diffusion coefficient map, axial and coronal T1 spin-echo before and after application of gadolinium, axial and coronal FLAIR, T2-weighted fast-field echo, and T2-weighted turbo spin-echo sequences were performed and evaluated by an experienced neuroradiologist (W.S.).

Histopathologic analysis.

For histopathologic analysis, sections from selective amygdalohippocampectomy specimen were incubated with antibodies against CD138, CD3, and CD8 antigen using standard methods, counterstained with hematoxylin & eosin.

For immunohistochemical analysis, slides were incubated 2 × 10 minutes in xylene, ethanol (100%-95%-70%-50%), and citrate buffer (10 mM, pH 6.0) and blocked for 2 hours at 37°C in blocking buffer consisting of 10% normal goat serum (Invitrogen) and 1% fetal calf serum (Invitrogen) in PBS. Slides were incubated with primary antibodies against CD8 (1:50, SP16 MA5-14548; Thermo Fisher) and Granzyme B Ab-1 (1:50, GZB01 MS-1157-S1; Thermo Fisher) overnight at room temperature in blocking buffer. After washing with PBS, slides were incubated with secondary antibodies (1:200 Alexa Fluor 488 donkey anti-mouse and 1:200 Alexa Fluor 568 goat anti-rabbit; both from Thermo Fisher) and with 0.1 μg/mL DAPI (4′,6-diamidino-2-phenylindole) (Life Technologies) for 2 hours at room temperature in blocking buffer. After washing with PBS, sections were coverslipped in fluorescein mounting medium (VECTASHIELD, Vector laboratories) and imaged with a confocal laser scanning microscope (Eclipse Ti, Nikon).

Statistics.

If not explicitly stated otherwise, all statistical analyses were performed using Sigma Plot 11 (Systat Software, Germany). Data were tested for normality using the Shapiro–Wilk test. All normally distributed data are given as mean together with the SD. All not normally distributed data are given as median together with the interquartile range. If not explicitly stated otherwise, the prechosen significance level for all confirmatory tests was set to p < 0.05. Levels of significance are indicated by n.s. (not significant) for all p > 0.05, * for all p < 0.05 and ** for all p < 0.01.

RESULTS

We identified 3 cases of nonparaneoplastic and one case of paraneoplastic GABAB-R LE associated with SCLC (3 women, 1 man, aged 42–60 years, 2 patients with a smoking history). A detailed case description is provided in appendix e-1. GABAB-receptor antibodies were detected in sera and/or CSF of all patients. One patient (patient 2) also exhibited GAD65 antibodies in serum but not CSF. All patients exhibited temporal lobe seizures, neuropsychological deficits (tables e-1 and e-2), and MRI (figure e-1, A and B) findings typical of LE. A tumor search was performed using whole-body 18F-fluorodeoxyglucose PET/CT together with urologic or gynecologic examination. Except for patient 4, all patients had normal white blood cell counts (appendix e-1) in the CSF. Time intervals between clinical disease onset and CSF analysis were short (2–8 weeks) in patients 1, 3, and 4 but long (5 years) in patient 2 (patient 1, 2 weeks; patient 2, about 5 years; patient 3, 8 weeks; patient 4, 4 weeks). At the time of CSF analysis, patients 1, 3, and 4 were immunotherapy-naive, whereas patient 2 had received several preceding immunotherapies all with marginal clinical effect suggesting persisting disease activity (see appendix e-1).

All patients underwent multiparameter flow cytometry analysis of PB and CSF to characterize the autoimmune response in GABAB-R LE in more detail (figures 1 and 2, table 1). A representative multiparameter flow cytometry analysis of PB and CSF in GABAB-R LE (patient 4) illustrating the gating strategy is given in figure e-2 (PB upper panels, CSF lower panels). Twenty-six patients who received CSF analysis for suspected neurologic disease but were found to have somatization disorders served as controls.

Figure 1
Figure 1 B cells and plasma cells accumulate in the CSF in GABAB receptor antibody–associated LE

Multiparameter flow cytometry analysis of absolute numbers of CD19+ B cells (A) and CD138+ CD19+ plasma cells (B) within PB and CSF in 4 patients with GABAB receptor antibody–associated LE and controls. Data are given as whisker plots. Levels of significance are indicated by n.s. (not significant) for all p > 0.05, * for all p < 0.05, and ** for all p < 0.01. For details, refer to the main text and table 1. GABAB = γ-aminobutyric acid B; LE = limbic encephalitis; PB = peripheral blood; Pt. = patient.

Figure 2
Figure 2 CD4+ and CD8+ T cells accumulate in the CSF in GABAB receptor antibody–associated LE

Multiparameter flow cytometry analysis of absolute numbers of CD4+ T cells (A) and CD8+ T cells (C), activated HLADR+ CD4+ T cells (B), and HLADR+ CD8+ T cells (D) within PB and CSF in 4 patients with GABAB receptor antibody–associated LE and controls. Data are given as whisker plots. Levels of significance are indicated by n.s. (not significant) for all p > 0.05, * for all p < 0.05, and ** for all p < 0.01. For details, refer to the main text and table 1. GABAB = γ-aminobutyric acid B; LE = limbic encephalitis; PB = peripheral blood; Pt. = patient.

View this table:
Table 1

Data of different cell types in peripheral blood and CSF in patients with limbic encephalitis compared to controls

Absolute numbers of CD19+ B cells (figure 1A, table 1) as well as CD4+ T cells (figure 2A, table 1) and CD8+ T cells (figure 2D, table 1) did not differ in PB but were elevated in CSF of patients with GABAB-R LE compared to controls, illustrating an intrathecal accumulation of B and T lymphocytes in GABAB-R LE.

Moreover, absolute numbers of activated CD138+ CD19+ B cells, i.e., plasma cells (figure 1B, table 1) as well as activated HLADR+ CD4+ (figure 2B, table 1) and HLADR+ CD8+ (figure 2D, table 1) T cells did not differ in PB but were elevated in CSF of patients with GABAB-R LE compared to controls.

Histopathologic assessment of selective amygdalohippocampectomy specimen from patient 2 (figure 3, A–D) revealed perivascular infiltrates of CD138+ plasma cells (figure 3A) and CD3+ T cells (figure 3B). CD8+ T cells (figure 3C) were predominantly detected within the brain parenchyma in close contact to neurons but not in perivascular regions, suggesting that perivascular CD3+ T cells are mainly CD4+ T cells. Parenchymal CD8+ T cells were activated expressing cytotoxic effector molecules (granzyme B; figure 3D).

Figure 3
Figure 3 A pathogenic role for CD8+ T cells in addition to plasma cell–derived autoantibodies in GABAB receptor antibody–associated limbic encephalitis

Histologic specimen of one patient with GABAB receptor antibody–associated limbic encephalitis following selective amygdalohippocampectomy revealed perivascular infiltrates of CD138+ plasma cells (A) and CD3+ T cells (B). CD8+ T cells (C) were predominantly detected within the brain parenchyma in close contact to neurons but not in perivascular regions, suggesting that perivascular CD3+ T cells are mainly CD4+ T cells (scale bar represents 50 μm in A–C; insets show magnification of 2 representative neurons in close contact with CD8+ T cells). Representative confocal triple staining (D) for DAPI, CD8 (red), and granzyme B (green) revealed expression of granzyme B (white arrow) in parenchymal CD8+ T cells (scale bar represents 10 μm in D). DAPI = 4′6-diamidino-2-phenylindole·2HCl; GABAB = γ-aminobutyric acid B.

The results of the neuropsychological assessment (tables e-1 and e-2) represent the cognitive functions of 3 of the 4 patients with GABAB-R LE. Because of the clinical condition, detailed neuropsychological assessment was impossible in patient 4. All tested patients had deficits in verbal working memory (Auditory Verbal Learning Test [AVLT] trial 1), learning ability (AVLT trial 5, AVLT trials 1–5), and retrieval performance (AVLT trial 6, AVLT trial 7) and some also in visuospatial ability (Rey Complex Figure Test) as well as processing speed and set shifting (Trail Making Test).

Hence, we tried to relate the neuropsychological deficits detected in patients with GABAB-R LE to immune cell infiltrates in their CSF (figure 4), which we consider closely reflect those present in the inflamed limbic system.

Figure 4
Figure 4 Relation of neuropsychological deficits and intrathecal immune cell subsets in GABAB receptor antibody–associated limbic encephalitis

Relation of neuropsychological deficits to the absolute numbers of CD138+ CD19+ plasma cells (A), activated HLADR+ CD4+ T cells (B), and activated HLADR+ CD8+ T cells (C) and within the CSF in 3 patients with GABAB receptor antibody–associated limbic encephalitis. The overall neuropsychological deficits are quantified as the total neuropsychological percentile rank sum, and the verbal memory retrieval performance is quantified as the respective percentile rank sum (see table e-2). For details, refer to the main text. GABAB = γ-aminobutyric acid B; Pt. = patient.

Indeed, higher absolute numbers of HLADR+ CD4+ T cells in CSF corresponded well to lower overall neuropsychological deficits quantified as the total neuropsychological percentile rank sum as well as to lower deficits in verbal memory retrieval performance quantified as the respective percentile rank sum (figure 4B). In contrast, higher absolute numbers of HLADR+ CD8+ T cells in CSF corresponded even stronger to higher overall neuropsychological deficits as well as to higher deficits in verbal memory retrieval performance (figure 4C). This suggests a pathogenic role of activated HLADR+ CD8+ T cells and a more regulatory function of activated HLADR+ CD4+ T cells in the adaptive autoimmune inflammation of the limbic system in GABAB-R LE.

Likewise, although on a lower level in terms of absolute cell numbers and less strongly, higher absolute CD138+ CD19+ plasma cell numbers in CSF were associated with more severe overall neuropsychological impairment as well as with more severe deficits in verbal memory retrieval performance (figure 4A) consistent with the known pathogenic role of autoantibodies in GABAB-R LE.

DISCUSSION

We used multiparameter flow cytometry of PB and CSF in combination with clinical and neuropsychological characterization and MRI to characterize the cellular autoimmune response in 3 cases of nonparaneoplastic GABAB-R LE (patients 1–3) and one case of paraneoplastic GABAB-R LE (patient 4) associated with SCLC in comparison to patients with somatization disorders as controls. All patients with GABAB-R LE exhibited neuropsychological deficits and MRI findings typical of LE.1,3,4 Three of them were studied very early in the disease course (4–8 weeks after disease onset) in a therapy-naive state (patients 1, 3, and 4) and one was in a non–therapy-naive state (patient 2) with a disease course of about 5 years necessitating amygdalohippocampectomy for seizure control. The long-standing disease course of the latter case (patient 2) is somewhat unusual for the so far known GABAB-R LE phenomenology. One may speculate that long-standing temporal lobe epilepsy might have triggered GABAB-R LE in an individual obviously prone to autoimmunity as revealed by the additional presence of GAD65 antibodies. Moreover, pronounced deterioration of cognitive function was observed following amygdalohippocampectomy with involvement of the contralateral temporal lobe consistent with boosting the antineuronal immune response due to liberation of neuronal antigens. All cases finally responded to immunotherapy consisting of methylprednisolone pulse therapy and immunoadsorption together with rituximab or chemotherapy in 2 of 4 cases.

As compared to controls, in patients with GABAB-R LE, CD19+ B cells, CD4+ T cells, and CD8+ T cells and their activated forms were enriched in absolute numbers in CSF. Consistently, histologic specimen of patient 2 following selective amygdalohippocampectomy revealed perivascular infiltrates of CD138+ plasma cells and CD4+ T cells whereas activated CD8+ T cells expressing cytotoxic effector molecules were detected within the brain parenchyma in close contact to neurons. Moreover, higher absolute numbers of activated HLADR+ CD4+ T cells in CSF corresponded to lower neuropsychological deficits, whereas higher absolute numbers of CD138+ CD19+ plasma cells and activated HLADR+ CD8+ T cells in CSF corresponded to higher neuropsychological deficits in patients with GABAB-R LE. This suggests a pathogenic role of CD8+ T cells in addition to the established role of plasma cell–derived autoantibodies4 as well as a more regulatory function of CD4+ T cells12 in the adaptive autoimmune inflammation of the limbic system in GABAB-R LE.

However, our data of course have several strong limitations, as (1) we only studied as few as 4 partially not therapy-naive patients with GABAB-R LE; (2) one patient had left amygdalohippocampectomy due to treatment-resistant temporal lobe epilepsy additionally impairing memory performance13,14 and potentially altering ongoing cerebral autoimmune reactions; (3) we used a restricted panel of flow cytometry parameters to analyze the cellular immune reaction in GABAB-R LE limiting the insight gained into details of the activation and differentiation status of the immune cells involved; and (4) we did not perform analysis of the B and T cell receptor repertoire in GABAB-R LE, which would have allowed more precise delineation of the antigen-driven activation of the immune cells involved.

Moreover, the association between increased numbers of CD138+ CD19+ plasma cells and HLADR+ CD8+ T cells in the CSF with neuropsychological deficits in patients 1, 2, and 3 per se does not prove a causative role of these lymphocyte subsets, and lymphocyte infiltrates detected in selective amygdalohippocampectomy specimen are not very prominent compared to classic onconeuronal autoimmunity.15 However, as there was no evidence of an underlying tumor, and GAD65 antibodies were only detected in serum but not CSF in patient 2, we do not consider this case to represent a GAD65 antibody–associated LE, which might also have explained the presence of parenchymal T cells.6 Moreover, widespread perivascular and parenchyma T cell infiltrates were detected at autopsy in a case of paraneoplastic encephalomyelitis with SCLC in which GABAB receptor antibodies could be detected together with onconeuronal antibodies against amphiphysin.1,16 Here, parenchymal CD8+ T cells were found in close apposition to neurons.1,16 Hence, one might speculate that occult tumors are underlying the T cell immune response in our patients.

Assuming that both the humoral as well as the cellular arm of the immune system are actively involved in the pathogenesis of GABAB-R LE, it is unclear which is the primary and which the secondary immune mechanism, and whether cellular and humoral effectors share the same target antigens.

In one less likely scenario, a primary CD8+ T cell–mediated autoimmune reaction against mesial temporal lobe neurons or other parenchymal cells triggers humoral autoimmunity toward GABAB receptors. In another, more likely scenario, expression of GABAB receptors by peripheral tumors4,17 or thymus18 drives the pathogenic immune response. GABAB receptor antibodies first bind to their receptors, disturb pre- and postsynaptic GABAergic inhibition, and promote increased activity states with excessive synchronization in mesial temporal lobe neuronal networks leading to epileptic seizures.4,19 Antibodies against GABAB receptors are mainly of the IgG1 subclass4 and may thus promote neuronal damage directly via complement activation and antibody-dependent cell-mediated cytotoxicity20 and thus trigger epitope and antigen-spreading through the release of intracellular neuronal antigens (such as GAD655). However, most antineuronal IgG1 autoantibodies seem to exert their pathogenic effects indirectly via crosslinking and subsequent internalization of their receptors without causing overt neuronal damage,21,–,24 and in GABAB-R LE, direct blocking antibody effects on the receptor without internalization have recently been suggested.25 Epileptic seizures per se have been reported to turn on neuronal expression of major histocompatibility complex (MHC) class I molecules26,–,28 and other neuronal proteins (such as Hu29) potentially rendering neurons targets for CD8+ T cells specific for a variety of neuronal antigens. Consistently, following temporal lobe seizures induced by certain chemoconvulsants in mice, a successive accumulation of CD8+ T cells in the mesial temporal lobe with a strong impact on epileptogenesis has been observed.30 Moreover, CD8+ T cells have been shown to dramatically affect neuronal excitability on the single cell and network level31,–,33 and may thus well contribute to the neuronal pathology in LE. This possibility should be considered when stratifying immunotherapeutic approaches in GABAB-R LE.

AUTHOR CONTRIBUTIONS

K.S.G. and C.M. recruited and treated the patients under the supervision of N.M., S.G.M., and H.W. and wrote the first draft of the manuscript. K.B. performed the neuropsychological testing under the supervision of H.L. and wrote the first draft of the manuscript. M.H. together with C.C.G. analyzed flow cytometry data. W.S. performed MRI analysis. M.G., A.J.B., and K.M.v.L. performed histopathologic analysis. M.L., G.W., C.E.E., and A.J.B. contributed 2 of the patients. N.M., S.G.M., and H.W. designed and supervised the project. All authors contributed to and approved the final manuscript.

STUDY FUNDING

This study has been supported by the Collaborative Research Centre CRC TR128 “Initiating/Effector Versus Regulatory Mechanisms in Multiple Sclerosis—Progress Towards Tackling the Disease” (project Z2 to H.W.) and the “Stiftung Neuromedizin,” Münster, Germany to C.C.G. and to N.M.

DISCLOSURE

K.S. Golombeck performed immunoabsorption for 5% of her time. K. Bönte, C. Mönig, K. van Loo, and M. Hartwig report no disclosures. W. Schwindt is an executive editor for Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren, received research support from BMBF. G. Widman and M. Lindenau report no disclosures. A.J. Becker received research support from Deutsche Forschungsgemeinschaft, the European Union's Seventh Framework Programme. M. Glatzel received research support from Janssen Pharmaceuticals. C.E. Elger served on the scientific advisory board for UCB Belgium, Destin, received honoraria from Pfizer, Eisai, Destin, UCM Belgium, received research support from DFG. H. Wiendl served on the scientific advisory board for Bayer Healthcare, Biogen Idec, Sanofi-Genzyme, Merck Serono, Novartis, Roche, Teva, received travel funding and/or speaker honoraria from Bayer Vital GmbH, Bayer Schering AG, Biogen, CSL Behring, EMD Serono, Fresenius Medical Care, Sanofi-Genzyme, Merck Serono, OmniaMed, Novartis, Teva, GlaxoSmithKline, GW Pharmaceuticals, is on the editorial board for PLoS One, Neurotherapeutics, has consulted for Biogen Idec, Merck Serono, Novartis, OmniaMed, Roche, Sanofi-Genzyme, received research support from Bayer Healthcare, Bayer Vital, Biogen Idec, Merck Serono, Novartis, Sanofi-Genzyme, Sanofi US, Teva Pharma, German Ministry for Education and Research, European Union, Interdisciplinary Centre of Clinical Research Muenster, PML Consortium, German Research Foundation, Else Kröbner Fresenius Foundation, Fresenius Foundation, Hertie Foundation, RE Children's Foundation. S.G. Meuth received travel funding and/or speaker honoraria from Almirall, Bayer Healthcare, Biogen, Genzyme, Merck Serono, Novartis, Roche, Teva, is on the editorial board for PLoS One, has consulted for Biogen, Genzyme, Merck Serono, Novartis, Roche, Teva, received research support from Bayer Healthcare, Biogen, Genzyme, Merck Serono, Novartis, Teva. H. Lohmann reports no disclosures. C.C. Gross received travel funding and speaker honoraria from Genzyme, Novartis Pharma GmbH, Bayer Healthcare, is a review editor for Frontiers in Immunology, received research support from German Research Foundation, and University of Münster. N. Melzer received travel funding and/or speaker honoraria from Biogen Idec, GlaxoSmithKline, Teva, Fresenius Medical Care, performed immunoabsorption for 5% of her time, received research support from Fresenius Medical Care. Go to Neurology.org/nn for full disclosure forms.

ACKNOWLEDGMENT

The authors thank Verena Schütte, Schumina Säuberlich, and Kerstin Gottschalk, Department of Neurology, University of Münster, Germany, for excellent technical assistance.

Footnotes

  • ↵* These authors contributed equally to this work.

  • Funding information and disclosures are provided at the end of the article. Go to Neurology.org/nn for full disclosure forms. The Article Processing Charge was paid by the authors.

  • Supplemental data at Neurology.org/nn

  • Received November 23, 2015.
  • Accepted in final form March 17, 2016.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.

REFERENCES

  1. 1.↵
    1. Hoftberger R,
    2. Titulaer MJ,
    3. Sabater L,
    4. et al
    . Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 2013;81:1500–1506.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Jeffery OJ,
    2. Lennon VA,
    3. Pittock SJ,
    4. Gregory JK,
    5. Britton JW,
    6. McKeon A
    . GABAB receptor autoantibody frequency in service serologic evaluation. Neurology 2013;81:882–887.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Dogan Onugoren M,
    2. Deuretzbacher D,
    3. Haensch CA,
    4. et al
    . Limbic encephalitis due to GABAB and AMPA receptor antibodies: a case series. J Neurol Neurosurg Psychiatry 2015;86:965–972.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Lancaster E,
    2. Lai M,
    3. Peng X,
    4. et al
    . Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 2010;9:67–76.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Boronat A,
    2. Sabater L,
    3. Saiz A,
    4. Dalmau J,
    5. Graus F
    . GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 2011;76:795–800.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Malter MP,
    2. Helmstaedter C,
    3. Urbach H,
    4. Vincent A,
    5. Bien CG
    . Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 2010;67:470–478.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Lueg G,
    2. Gross CC,
    3. Lohmann H,
    4. et al
    . Clinical relevance of specific T-cell activation in the blood and cerebrospinal fluid of patients with mild Alzheimer's disease. Neurobiol Aging 2015;36:81–89.
    OpenUrl
  8. 8.↵
    1. Zettl UK,
    2. Lehmitz R,
    3. Mix E
    . Klinische Liquordiagnostik. Berlin: Walter de Gruyter; 2005.
  9. 9.↵
    1. de Graaf MT,
    2. de Jongste AH,
    3. Kraan J,
    4. Boonstra JG,
    5. Sillevis Smitt PA,
    6. Gratama JW
    . Flow cytometric characterization of cerebrospinal fluid cells. Cytometry B Clin Cytom 2011;80:271–281.
    OpenUrlPubMed
  10. 10.↵
    1. Melzer N,
    2. Meuth SG,
    3. Wiendl H
    . Neuron-directed autoimmunity in the central nervous system: entities, mechanisms, diagnostic clues, and therapeutic options. Curr Opin Neurol 2012;25:341–348.
    OpenUrlPubMed
  11. 11.↵
    1. Lancaster E,
    2. Dalmau J
    . Neuronal autoantigens: pathogenesis, associated disorders and antibody testing. Nat Rev Neurol 2012;8:380–390.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Gobel K,
    2. Bittner S,
    3. Melzer N,
    4. et al
    . CD4(+) CD25(+) FoxP3(+) regulatory T cells suppress cytotoxicity of CD8(+) effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level. J Neuroinflammation 2012;9:41.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Helmstaedter C
    . Cognitive outcomes of different surgical approaches in temporal lobe epilepsy. Epileptic Disord 2013;15:221–239.
    OpenUrlPubMed
  14. 14.↵
    1. von Rhein B,
    2. Nelles M,
    3. Urbach H,
    4. Von Lehe M,
    5. Schramm J,
    6. Helmstaedter C
    . Neuropsychological outcome after selective amygdalohippocampectomy: subtemporal versus transsylvian approach. J Neurol Neurosurg Psychiatry 2012;83:887–893.
    OpenUrlAbstract/FREE Full Text
  15. 15.↵
    1. McKeon A,
    2. Pittock SJ
    . Paraneoplastic encephalomyelopathies: pathology and mechanisms. Acta Neuropathol 2011;122:381–400.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Graus F,
    2. Saiz A,
    3. Lai M,
    4. et al
    . Neuronal surface antigen antibodies in limbic encephalitis: clinical-immunologic associations. Neurology 2008;71:930–936.
    OpenUrlCrossRef
  17. 17.↵
    1. Dalmau J,
    2. Rosenfeld MR
    . Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7:327–340.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Alexopoulos H,
    2. Dagklis IE,
    3. Akrivou S,
    4. Bostantjopoulou S,
    5. Dalakas MC
    . Autoimmune encephalitis with GABAB antibodies, thymoma, and GABAB receptor thymic expression. Neurol Neuroimmunol Neuroinflamm 2014;1:e39.
    OpenUrl
  19. 19.↵
    1. Emson PC
    . GABA(B) receptors: structure and function. Prog Brain Res 2007;160:43–57.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Melzer N,
    2. Meuth SG,
    3. Wiendl H
    . Paraneoplastic and non-paraneoplastic autoimmunity to neurons in the central nervous system. J Neurol 2013;260:1215–1233.
    OpenUrl
  21. 21.↵
    1. Hughes EG,
    2. Peng X,
    3. Gleichman AJ,
    4. et al
    . Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci 2010;30:5866–5875.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Ohkawa T,
    2. Satake S,
    3. Yokoi N,
    4. et al
    . Identification and characterization of GABA(A) receptor autoantibodies in autoimmune encephalitis. J Neurosci 2014;34:8151–8163.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Peng X,
    2. Hughes EG,
    3. Moscato EH,
    4. Parsons TD,
    5. Dalmau J,
    6. Balice-Gordon RJ
    . Cellular plasticity induced by anti-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor encephalitis antibodies. Ann Neurol 2015;77:381–398.
    OpenUrlPubMed
  24. 24.↵
    1. Petit-Pedrol M,
    2. Armangue T,
    3. Peng X,
    4. et al
    . Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol 2014;13:276–286.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Jain A,
    2. Lancaster E,
    3. Dalmau J,
    4. Balice-Gordon RJ
    . Autoantibodies in the CSF of anti-GABAB receptor encephalitis patients block activation of GABAB receptors in vitro. Ann Neurol 2015;78:77.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Corriveau RA,
    2. Huh GS,
    3. Shatz CJ
    . Regulation of class I MHC gene expression in the developing and mature CNS by neural activity. Neuron 1998;21:505–520.
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Neumann H,
    2. Cavalie A,
    3. Jenne DE,
    4. Wekerle H
    . Induction of MHC class I genes in neurons. Science 1995;269:549–552.
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Neumann H,
    2. Schmidt H,
    3. Cavalie A,
    4. Jenne D,
    5. Wekerle H
    . Major histocompatibility complex (MHC) class I gene expression in single neurons of the central nervous system: differential regulation by interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. J Exp Med 1997;185:305–316.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Tiruchinapalli DM,
    2. Ehlers MD,
    3. Keene JD
    . Activity-dependent expression of RNA binding protein HuD and its association with mRNAs in neurons. RNA Biol 2008;5:157–168.
    OpenUrlCrossRefPubMed
  30. 30.↵
    1. Zattoni M,
    2. Mura ML,
    3. Deprez F,
    4. et al
    . Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy. J Neurosci 2011;31:4037–4050.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Ehling P,
    2. Melzer N,
    3. Budde T,
    4. Meuth SG
    . CD8(+) T cell-mediated neuronal dysfunction and degeneration in limbic encephalitis. Front Neurol 2015;6:163.
    OpenUrl
  32. 32.↵
    1. Meuth SG,
    2. Herrmann AM,
    3. Simon OJ,
    4. et al
    . Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death. J Neurosci 2009;29:15397–15409.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Chevalier G,
    2. Suberbielle E,
    3. Monnet C,
    4. et al
    . Neurons are MHC class I-dependent targets for CD8 T cells upon neurotropic viral infection. PLoS Pathog 2011;7:e1002393.
    OpenUrlCrossRefPubMed

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Topics Discussed

Alert Me

Recommended articles